SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-056224
Filing Date
2024-06-26
Accepted
2024-06-26 17:20:41
Documents
16
Period of Report
2024-06-21
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0208510-8k_unicycive.htm   iXBRL 8-K 26495
2 CERTIFICATE OF AMENDMENT ea020851001ex3-1_unicycive.htm EX-3.1 1824
3 GRAPHIC ex3-1_001.jpg GRAPHIC 337338
4 GRAPHIC ex3-1_002.jpg GRAPHIC 278288
  Complete submission text file 0001213900-24-056224.txt   1053232

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE uncy-20240621.xsd EX-101.SCH 3018
6 XBRL LABEL FILE uncy-20240621_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE uncy-20240621_pre.xml EX-101.PRE 22361
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0208510-8k_unicycive_htm.xml XML 3901
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

IRS No.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40582 | Film No.: 241074562
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)